NT 112
Alternative Names: NT-112Latest Information Update: 14 Jul 2024
At a glance
- Originator Neogene Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 15 Feb 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in USA (Parenteral) (NCT06218914)
- 30 Jan 2024 Preclinical trials in Solid tumours in USA (Parenteral) (Neogen Therapeutics pipeline, January 2024)